Lil­ly's Trulic­i­ty CV out­comes da­ta un­der­whelm amid block­buster di­a­betes ri­val­ry with No­vo

Eli Lil­ly has suf­fered a mi­nor de­feat in the block­buster di­a­betes ri­val­ry as an­a­lysts size up the car­dio­vas­cu­lar out­comes for Trulic­i­ty against No­vo Nordisk’s prod­ucts.

To be sure, Lil­ly was in a cel­e­bra­to­ry mood about the REWIND tri­al, the longest of such stud­ies with­in the GLP-1 class. Their drug scored a 12% re­duc­tion in ma­jor car­dio­vas­cu­lar events (MACE), dri­ven by all three com­pos­ite mea­sures span­ning non-fa­tal heart at­tack, non-fa­tal stroke and CV death — re­gard­less of whether the pa­tients had es­tab­lished CV dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER